Pediatric Breathalyzer Identifies Disease by Analyzing Exhalations
By HospiMedica International staff writers Posted on 19 Oct 2016 |
Image: The ReCIVA breathalyzer (Photo courtesy of Owlstone Medical).
A novel breath-testing device aids early stage diagnostics and therapy response in both adults and child asthma patients.
The Respiration Collector for In Vitro Analysis (ReCIVA) device is designed to accurately and selectively detect volatile organic compounds (VOCs) in breath that have been shown to correlate to inflammatory subtype in asthma, and can thus help guide better treatment decisions. ReCIVA is used in combination with the proprietary field asymmetric ion mobility spectrometer (FAIMS) sensor platform, a technology that can be programmed in software to detect targeted biomarkers of disease not only in breath, but in bodily fluids as well.
FAIMS can be also used in clinical diagnostics and precision medicine, with applications both in cancer and in a wide range of other medical conditions. The highly sensitive and selective tests allow for early diagnosis when treatment is more effective, resulting in more lives saved. The ReCIVA breathalyzer platform was adapted to a pediatric version intended for children five years of ages and up, offering a completely non-invasive way to test children’s breath.
Both the adult and pediatric versions of the breathalyzer have been implemented in the East Midlands Breathomics Pathology Node (EMBER), a £2.5 million project with the primary aims being development of breath-based systems for molecular pathology of disease, and clinically validating breathomics as a viable diagnostic modality. The ReCIVA breathalyzer is a product of Owlstone Medical (Cambridge, United Kingdom), and has received the European Community CE mark of approval.
“Breath analysis presents a significant opportunity to better predict how a child will respond to certain treatments, including steroids and expensive biologics,” said Billy Boyle, co-founder and CEO of Owlstone Medical. “In developing a pediatric breath sampler we are expanding the scope of projects such as EMBER to include children as an important group in the study of asthma, and more generally extending other biomarker and discovery studies using breath.”
“Choosing the right treatment for the right patient is especially challenging in children, as obtaining samples such as blood to measure disease activity can be difficult,” said professor of respiratory medicine Chris Brightling, PhD, of the University of Leicester (United Kingdom) and EMBER. “Breath analysis offers an excellent opportunity to sample the airway by simply breathing into a mask. This presents a new approach to understand disease and make better treatment decisions.”
Related Links:
Owlstone Medical
The Respiration Collector for In Vitro Analysis (ReCIVA) device is designed to accurately and selectively detect volatile organic compounds (VOCs) in breath that have been shown to correlate to inflammatory subtype in asthma, and can thus help guide better treatment decisions. ReCIVA is used in combination with the proprietary field asymmetric ion mobility spectrometer (FAIMS) sensor platform, a technology that can be programmed in software to detect targeted biomarkers of disease not only in breath, but in bodily fluids as well.
FAIMS can be also used in clinical diagnostics and precision medicine, with applications both in cancer and in a wide range of other medical conditions. The highly sensitive and selective tests allow for early diagnosis when treatment is more effective, resulting in more lives saved. The ReCIVA breathalyzer platform was adapted to a pediatric version intended for children five years of ages and up, offering a completely non-invasive way to test children’s breath.
Both the adult and pediatric versions of the breathalyzer have been implemented in the East Midlands Breathomics Pathology Node (EMBER), a £2.5 million project with the primary aims being development of breath-based systems for molecular pathology of disease, and clinically validating breathomics as a viable diagnostic modality. The ReCIVA breathalyzer is a product of Owlstone Medical (Cambridge, United Kingdom), and has received the European Community CE mark of approval.
“Breath analysis presents a significant opportunity to better predict how a child will respond to certain treatments, including steroids and expensive biologics,” said Billy Boyle, co-founder and CEO of Owlstone Medical. “In developing a pediatric breath sampler we are expanding the scope of projects such as EMBER to include children as an important group in the study of asthma, and more generally extending other biomarker and discovery studies using breath.”
“Choosing the right treatment for the right patient is especially challenging in children, as obtaining samples such as blood to measure disease activity can be difficult,” said professor of respiratory medicine Chris Brightling, PhD, of the University of Leicester (United Kingdom) and EMBER. “Breath analysis offers an excellent opportunity to sample the airway by simply breathing into a mask. This presents a new approach to understand disease and make better treatment decisions.”
Related Links:
Owlstone Medical
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure